The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy

NCT01181765 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

1

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn's Disease

Interventions

BIOLOGICAL: Infliximab 5 mg/kg body weight infused over 2 hours

Sponsor

Janssen Inc.